// App-Quantinova.ai

TPS185 : Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).

Researchers

Presenter

  • Amna Falak Sher

Principal Investigators

  • Justine Yang Bruce

  • Nashat Y. Gabrail

  • Ian Churchill Anderson

  • Anna Patrikidou

  • Rachel E. Sanborn

  • Jae Yong Cho

  • Arielle Shebay Lee

  • Jong-Seok Lee

  • Louise M. Nott

  • Do-Youn Oh

  • Sang Cheul Oh

  • Sung Yong Oh

  • Yinghui Wang

  • Zejing Wang

  • Troy H. Guthrie

Medical Centers

  • Stony Brook University, Stony Brook, NY

  • Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI

  • Gabrail Cancer Center Research LLC, Canton, OH

  • St Joseph Heritage Healthcare, Santa Rosa, CA

  • Sarah Cannon Research Institute, London, United Kingdom

  • Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR

  • Severence Hospital, Yonsei University, Seoul, South Korea

  • HOPE Cancer Center of East Texas, Tyler, TX

  • Pediatrics, Seoul National University Bundang Hospital, Gyeonggi-do, Korea

  • Royal Hobart Hospital, Hobart, Australia

  • Korea University Guro Hospital, Seoul, Korea

  • Dong-A University Hospital, Busan, South Korea,

  • Seattle Genetics, Bothell, WA

  • 21st Century Oncology, Jacksonville, FL

Locations

  • United States

  • United Kingdom

  • Republic of South Korea

  • Australia

Companies

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Solid malignancies

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

  • Solute Carrier Family 39 Member 6

  • BRCA mutation

Drug/Treatment

  • SGN-LIV1A

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Cohort

Phase

  • II

Study Id's

  • NCT04032704

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved